{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 10,
  "pageCount": 54,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a structured layout to compare three distinct product pipelines.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/10",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.25,
        "x": 0.68,
        "y": 0.26
      },
      "kind": "callout",
      "text": "Potential first-in-category hormone-free contraception. Self-administered intravaginal drug/device",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f4155ad-c18a-4865-bbf0-c95ed51eda74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.25,
        "x": 0.68,
        "y": 0.47
      },
      "kind": "callout",
      "text": "Potential first-in-category treatment for female sexual arousal disorder (FSAD). Topical cream, same active ingredient as Viagra",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43ef3fcc-270a-4d89-8847-1d3df0bbb2ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.25,
        "x": 0.68,
        "y": 0.68
      },
      "kind": "callout",
      "text": "Potential first-in-category vaginal combination hormone delivery for treatment of vasomotor symptoms due to menopause. Self-administered 28-day IVR",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5868ec7d-5d24-41a1-a369-e1735200f0c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.07,
        "x": 0.33,
        "y": 0.28
      },
      "kind": "image",
      "text": "Bayer and NIH logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8a9865c-1e83-4537-9cc3-c0f726a5b850",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.07,
        "y": 0.65
      },
      "kind": "list",
      "text": "DARE-HRT1: Hormone Therapy. Phase 1 / 2 Completed – IND and Phase 3 Preparations Underway.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48b86045-cee4-4fdf-a437-fb32e13ea4da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "list",
      "text": "Ovaprene: Hormone-Free, Monthly Contraception. Pivotal Phase 3 Study to Commence 2023.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edc170c0-2e58-4f6c-ba4e-785001d1d1d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.07,
        "y": 0.44
      },
      "kind": "list",
      "text": "Sildenafil Cream, 3.6%: Female Sexual Arousal Disorder. Phase 2b Study Topline Data Anticipated 2Q-2023.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efb2b47b-d712-41dd-8622-fb62a9cd63b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.16,
        "y": 0.15
      },
      "kind": "title",
      "text": "Advancing Products Women Want – Late Stage Programs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86305da8-d95a-41a2-aad3-f6efe1f0d397",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}